Chantix
(Varenicline Tartrate)ApprovedSmall molecule
PfizerVarenicline Tartrate is used to help people quit smoking by reducing cravings and blocking the rewarding effects of nicotine in the brain.[2] Chantix is currently approved and in use across 7 indications[4].[1]
Chantix is one of 185 small molecule programs targeting Nicotine Dependence. It is currently in Approved.
7
Indications
23
Total Trials
2
Active Trials
184
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Chantix
PfizerApproved
Veramyst
GSKPreclinical
Flovent
GSKPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Narcan
SScienture
Preclinical
Coumadin
AAbbott
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Absorption4 trials
Smokers3 trials
Smoking Cessation3 trials
Psychiatric Disorder2 trials
9 more indications
Smokeless Tobacco1 trial
Effectiveness1 trial
Tobacco Use Disorder1 trial
Chronic Obstructive Pulmonary Disease1 trial
Efficacy1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Chantix drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Varenicline Tartrate. EMBL-EBI & Wellcome Sanger Institute.
- [5]